Abstract: Objective Objective to investigate the application effect of cefuroxime sodium and ceftizoxime sodium in the treatment of children with acute bronchial pneumonia and the animal vascular cell adhesion molecule-1 (VCAM-1) and its clinical significance γ Interferon (IFN-γ) Horizontal impact. Methods All 82 children with bronchopneumonia admitted to Hancheng Maternal and Child Health Hospital from August 2021 to July 2023 were selected for retrospective analysis, and randomly divided into cefuroxime sodium group and ceftizoxime sodium group, 41 cases in each group. All children were treated with routine maintenance of water electrolyte, acid-base balance, sputum suction, heat clearing, asthma relieving, cough relieving and other symptomatic treatment, and were treated with budesonide atomization inhalation and azithromycin oral treatment. The children in Cefuroxime Sodium group were given cefuroxime sodium intravenous drip on the basis of conventional treatment, while the children in ceftizoxime sodium group were given ceftizoxime sodium intravenous drip on the basis of conventional treatment. The disappearance time of pulmonary rales/wheezes, cough, total days of fever, imaging recovery time, VCAM-1 and IFN before and after treatment were compared between the two groups-γ, The expression levels of PCT and CRP were compared between the two groups. Results The disappearance time of pulmonary rales/wheezes, cough, total days of fever and imaging recovery time in Cefuroxime Sodium group were significantly lower than those in ceftizoxime sodium group (P<0.05); VCAM-1 and IFN of the two groups before treatment-γ. There was no significant difference in the expression levels of PCT and CRP between the two groups (P>0.05). After treatment, the levels of VCAM-1, PCT and CRP in the two groups were decreased, and the level of IFN in the cefuroxime sodium group was lower than that in the ceftizoxime sodium group-γ The serum level in Cefuroxime Sodium group was higher than that in ceftizoxime sodium group (P<0.05); No severe adverse reactions such as renal function injury and blood system injury occurred in the two groups, and there was no significant difference in adverse reactions such as nausea and vomiting, dizziness, skin allergy and diarrhea between the two groups (P>0.05). Conclusion Cefuroxime sodium is better than ceftizoxime sodium in the application of children with acute bronchial pneumonia, which can shorten the duration of symptoms, relieve the accumulation of inflammatory cytokines, reduce the body's inflammatory reaction, and has high safety.

Key words: cefuroxime sodium, ceftizoxime sodium, acute bronchopneumonia, animal vascular cell adhesion molecule-1, γ interferon